<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene N440K literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.N440K</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Experimentally, ACE2 binding affinity increased 0.07 fold (<a href="https://doi.org/10.1016/j.cell.2020.08.012" class="lit_link">Starr et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. <br/> (<a href="https://doi.org/10.1101/2020.11.03.367391" class="lit_link">Gaebler et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).<br/> (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555.<br/>Abolishes binding of mAb ADG-1. (<a href="https://doi.org/10.1126/science.abf4830" class="lit_link">Rappazzo et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23 (<a href="https://doi.org/10.1186/s12985-021-01554-8" class="lit_link">Cheng et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).<br/> (<a href="https://doi.org/10.1101/2021.01.15.426911" class="lit_link">Wang et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages (<a href="https://doi.org/10.1101/2020.07.21.214759" class="lit_link">Weisblum et al. (2020)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in neutralization efficacy using a VSV model on Vero E6 cells.<br/> (<a href="https://doi.org/10.1101/2021.03.09.434607v9" class="lit_link">Cathcart et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="transmissibility">Transmissibility</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.<br/>Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.<br/> (<a href="https://doi.org/10.1101/2021.04.30.441434" class="lit_link">Tandel et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
